STOCK TITAN

Ionis Pharmaceuticals (IONS) awards 3,399 RSUs to board director Reikes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Reikes Peter N reported acquisition or exercise transactions in this Form 4 filing.

Ionis Pharmaceuticals Inc granted director Peter N Reikes 3,399 Restricted Stock Units on July 15, 2026 under its Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. The RSUs vest in three equal annual installments starting July 15, 2027 and will be fully vested on July 15, 2029. Following this award, Reikes holds 3,399 RSUs directly, all unvested as of the grant date.

Positive

  • None.

Negative

  • None.
Insider Reikes Peter N
Role Director
Type Security Shares Price Value
Grant/Award Restricted Stock Unit 3,399 $0.00 --
Holdings After Transaction: Restricted Stock Unit — 3,399 shares (Direct)
Footnotes (1)
  1. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. Grant on July 15, 2026 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in three equal annual installments, the first installment vesting on July 15, 2027. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 15, 2029. The RSU is vested as to 0 shares on July 15, 2026.
RSUs granted 3,399 Restricted Stock Units Grant to director Peter N Reikes on July 15, 2026
Underlying common shares 3,399 shares of Common Stock Each RSU represents a contingent right to one share or its cash value
Vesting installments 3 equal annual installments First installment vests on July 15, 2027
Full vesting date July 15, 2029 RSU award shall be fully vested on this date
Post-grant RSU holdings 3,399 Restricted Stock Units Total direct RSU holdings following the reported transaction
Restricted Stock Unit financial
"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
contingent right financial
"represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value"
Amended and Restated 2002 Non-Employee Directors' Stock Option Plan financial
"Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What equity award did Ionis Pharmaceuticals (IONS) grant to Peter N Reikes?

Ionis Pharmaceuticals granted director Peter N Reikes 3,399 Restricted Stock Units on July 15, 2026. Each unit provides a contingent right to receive one share of Ionis common stock or its equivalent cash value, subject to a multi-year vesting schedule through July 15, 2029.

How do the Ionis Pharmaceuticals (IONS) RSUs for Peter N Reikes vest over time?

The 3,399 RSUs granted to Peter N Reikes vest in three equal annual installments. The first installment vests on July 15, 2027, with additional installments on the following two anniversaries, so the award is fully vested on July 15, 2029.

When will the Ionis Pharmaceuticals (IONS) RSUs granted to Peter N Reikes be fully vested?

The RSU award to Peter N Reikes is scheduled to be fully vested on July 15, 2029. Vesting occurs in three equal annual installments beginning July 15, 2027, and no shares were vested as of the grant date, July 15, 2026.

What does each Restricted Stock Unit represent in the Ionis (IONS) grant to Peter N Reikes?

Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. Upon vesting, the RSUs will be settled in whole shares of common stock or cash, as may be determined by the company.

How many Ionis Pharmaceuticals (IONS) RSUs does Peter N Reikes hold after this grant?

Following the July 15, 2026 grant, Peter N Reikes holds 3,399 Restricted Stock Units directly. According to the grant terms, the RSUs are vested as to 0 shares on the grant date, with vesting commencing in 2027 and finishing in 2029.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Reikes Peter N

(Last)(First)(Middle)
2855 GAZELLE COURT

(Street)
CARLSBAD CALIFORNIA 92010

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit$0.0(1)07/15/2026A3,399 (2) (2)Common Stock3,399$0.03,399D
Explanation of Responses:
1. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
2. Grant on July 15, 2026 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in three equal annual installments, the first installment vesting on July 15, 2027. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 15, 2029. The RSU is vested as to 0 shares on July 15, 2026.
By: Patrick R. O'Neil, attorney-in-fact For: Peter N. Reikes07/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)